======= E2F7 ======= == Gene Information == * **Official Symbol**: E2F7 * **Official Name**: E2F transcription factor 7 * **Aliases and Previous Symbols**: N/A * **Entrez ID**: [[https://www.ncbi.nlm.nih.gov/gene/?term=144455|144455]] * **UniProt**: [[https://www.uniprot.org/uniprot/Q96AV8|Q96AV8]] * **Interactions**: [[https://thebiogrid.org/search.php?search=E2F7&organism=9606|BioGRID]] * **PubMed articles**: [[https://www.ncbi.nlm.nih.gov/pubmed/?term=gene%20E2F7|Open PubMed]] * **OMIM**: [[https://omim.org/entry/612046|Open OMIM]] == Function Summary == * **Entrez Summary**: N/A * **UniProt Summary**: Atypical E2F transcription factor that participates in various processes such as angiogenesis, polyploidization of specialized cells and DNA damage response. Mainly acts as a transcription repressor that binds DNA independently of DP proteins and specifically recognizes the E2 recognition site 5'- TTTC[CG]CGC-3'. Directly represses transcription of classical E2F transcription factors such as E2F1. Acts as a regulator of S-phase by recognizing and binding the E2-related site 5'-TTCCCGCC-3' and mediating repression of G1/S-regulated genes. Plays a key role in polyploidization of cells in placenta and liver by regulating the endocycle, probably by repressing genes promoting cytokinesis and antagonizing action of classical E2F proteins (E2F1, E2F2 and/or E2F3). Required for placental development by promoting polyploidization of trophoblast giant cells. Also involved in DNA damage response: up-regulated by p53/TP53 following genotoxic stress and acts as a downstream effector of p53/TP53-dependent repression by mediating repression of indirect p53/TP53 target genes involved in DNA replication. Acts as a promoter of sprouting angiogenesis, possibly by acting as a transcription activator: associates with HIF1A, recognizes and binds the VEGFA promoter, which is different from canonical E2 recognition site, and activates expression of the VEGFA gene. Acts as a negative regulator of keratinocyte differentiation. {ECO:0000269|PubMed:14633988, ECO:0000269|PubMed:15133492, ECO:0000269|PubMed:18202719, ECO:0000269|PubMed:19223542, ECO:0000269|PubMed:21248772, ECO:0000269|PubMed:22802528, ECO:0000269|PubMed:22802529, ECO:0000269|PubMed:22903062}. |E2F TDP| |positive regulation of DNA endoreduplication| |negative regulation of transcription involved in G1/S transition of mitotic cell cycle| |chorionic trophoblast cell differentiation| |chorion development| |negative regulation of cytokinesis| |extraembryonic membrane development| |regulation of DNA endoreduplication| |positive regulation of DNA-dependent DNA replication| |trophoblast giant cell differentiation| |hepatocyte differentiation| |negative regulation of cell division| |cell differentiation involved in embryonic placenta development| |regulation of transcription involved in G1/S transition of mitotic cell cycle| |proximal promoter sequence-specific DNA binding| |positive regulation of DNA replication| |regulation of DNA-dependent DNA replication| |DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest| |signal transduction involved in mitotic G1 DNA damage checkpoint| |signal transduction involved in mitotic cell cycle checkpoint| |signal transduction involved in mitotic DNA damage checkpoint| |intracellular signal transduction involved in G1 DNA damage checkpoint| |signal transduction involved in mitotic DNA integrity checkpoint| |sprouting angiogenesis| |mitotic G1 DNA damage checkpoint| |mitotic G1/S transition checkpoint| |G1 DNA damage checkpoint| |signal transduction involved in DNA integrity checkpoint| |signal transduction involved in DNA damage checkpoint| |RNA polymerase II transcription factor complex| |signal transduction involved in cell cycle checkpoint| |DNA damage response, signal transduction by p53 class mediator| |positive regulation of cell cycle arrest| |embryonic placenta development| |regulation of cytokinesis| |mitotic DNA damage checkpoint| |negative regulation of G1/S transition of mitotic cell cycle| |mitotic DNA integrity checkpoint| |signal transduction in response to DNA damage| |negative regulation of cell cycle G1/S phase transition| |regulation of cell cycle arrest| |regulation of DNA replication| |G1/S transition of mitotic cell cycle| |signal transduction by p53 class mediator| |cell cycle G1/S phase transition| |liver development| |hepaticobiliary system development| |DNA damage checkpoint| |DNA integrity checkpoint| |regulation of G1/S transition of mitotic cell cycle| |placenta development| |mitotic cell cycle checkpoint| |regulation of cell cycle G1/S phase transition| |regulation of cell division| |cell cycle checkpoint| |negative regulation of mitotic cell cycle phase transition| |negative regulation of cell cycle phase transition| |transcription corepressor activity| |DNA-binding transcription repressor activity, RNA polymerase II-specific| |mitotic cell cycle phase transition| |cell cycle phase transition| |positive regulation of cell cycle process| |negative regulation of mitotic cell cycle| |angiogenesis| |negative regulation of cell cycle process| |transcription factor binding| |in utero embryonic development| |positive regulation of cell cycle| |nuclear speck| |blood vessel morphogenesis| |gland development| |regulation of mitotic cell cycle phase transition| |sequence-specific DNA binding| |reproductive structure development| |reproductive system development| |embryonic organ development| |regulation of cell cycle phase transition| |blood vessel development| |RNA polymerase II proximal promoter sequence-specific DNA binding| |vasculature development| |cardiovascular system development| |negative regulation of cell cycle| |mitotic cell cycle process| |regulation of mitotic cell cycle| |chordate embryonic development| |embryo development ending in birth or egg hatching| |tube morphogenesis| |developmental process involved in reproduction| |DNA-binding transcription factor activity| |negative regulation of cell population proliferation| |epithelial cell differentiation| |mitotic cell cycle| |regulation of cell cycle process| |cellular response to DNA damage stimulus| |tube development| |negative regulation of transcription by RNA polymerase II| |circulatory system development| |anatomical structure formation involved in morphogenesis| |embryo development| |cell cycle process| |identical protein binding| |epithelium development| |regulation of cell cycle| |negative regulation of transcription, DNA-templated| |positive regulation of transcription by RNA polymerase II| |negative regulation of nucleic acid-templated transcription| |negative regulation of RNA biosynthetic process| |negative regulation of RNA metabolic process| |cell cycle| |negative regulation of cellular macromolecule biosynthetic process| |reproductive process| |reproduction| |negative regulation of nucleobase-containing compound metabolic process| |DNA binding| |negative regulation of macromolecule biosynthetic process| |negative regulation of cellular biosynthetic process| |positive regulation of transcription, DNA-templated| |negative regulation of biosynthetic process| |DNA-binding transcription factor activity, RNA polymerase II-specific| |regulation of cell population proliferation| |positive regulation of nucleic acid-templated transcription| |positive regulation of RNA biosynthetic process| |intracellular signal transduction| |cellular response to stress| |negative regulation of gene expression| |positive regulation of RNA metabolic process| |tissue development| |positive regulation of nucleobase-containing compound metabolic process| |positive regulation of macromolecule biosynthetic process| |positive regulation of cellular biosynthetic process| |positive regulation of gene expression| |positive regulation of biosynthetic process| \\ === CRISPR Data === ^Screen^Score^ |[[:results:exp134|MS023 2μM R03 exp134]]|-1.88| |[[:results:exp170|Metformin 100 to 150μM on day4 R04 exp170]]|1.76| |[[:results:exp306|Rapamycin 2μM R07 exp306]]|1.88| |[[:results:exp335|Aminopterin 0.005μM R07 exp335]]|2.34| |[[:results:exp501|Methotrexate 0.01μM R08 exp501]]|2.48| No correlation found to any other genes in chemogenomics. Global Fraction of Cell Lines Where Essential: 0/726 ^Tissue^Fraction Of Cell Lines Where Essential^ |1290807.0|0/1| |909776.0|0/1| |bile duct|0/28| |blood|0/28| |bone|0/25| |breast|0/33| |central nervous system|0/56| |cervix|0/4| |colorectal|0/17| |esophagus|0/13| |fibroblast|0/1| |gastric|0/15| |kidney|0/21| |liver|0/20| |lung|0/75| |lymphocyte|0/14| |ovary|0/26| |pancreas|0/24| |peripheral nervous system|0/16| |plasma cell|0/15| |prostate|0/1| |skin|0/24| |soft tissue|0/7| |thyroid|0/2| |upper aerodigestive|0/22| |urinary tract|0/29| |uterus|0/5| == Essentiality in NALM6 == * **Essentiality Rank**: 15535 * **Expression level (log2 read counts)**: 5.61 {{:chemogenomics:nalm6 dist.png?nolink |}}